Saphenous Vein Graft

Landmark Study for Embolic Protection

Significant reduction in MACE with use of Embolic Protection (EP)^4*

SAFER Trial - Study Objective:

• 801 patients receiving SVG PCI
• 406 procedures performed with embolic protection
• Enpoint: Cumulative incidence of MACE rate at 30 days^†

* The SAFER Trial studied the GuardWire Plus System versus No Protection in SVG interventions

† MACE defined as the composite of death, myocardial infarction (MI), emergency bypass, or target lesion revascularization

SAFER/FIRE Trials: Demonstrated Reduction in Total 30-Day MACE^4,5

FIRE Trial Study Conclusion:

Distal protection with FilterWire EX may be safely used as an adjuct to PCI of diseased SVGs and results in similar rates of MACE at 30 days, compared with distal protection with the GuardWire balloon occlusion and aspiration system.